Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment
| dc.contributor.author | Oreja-Guevara, C. | |
| dc.contributor.author | Bermel, R. | |
| dc.contributor.author | Comi, G. | |
| dc.contributor.author | Eralinna, J. -P. | |
| dc.contributor.author | Leist, T. P. | |
| dc.contributor.author | Nicholas, R. | |
| dc.contributor.author | Van Wijmeersch, B. | |
| dc.contributor.author | Wiendl, H. | |
| dc.contributor.author | Bernasconi, C. | |
| dc.contributor.author | Buffels, R. | |
| dc.contributor.author | Csoboth, C. | |
| dc.contributor.author | Han, J. | |
| dc.contributor.author | Musch, B. | |
| dc.contributor.author | Vermersch, P. | |
| dc.contributor.author | Siva, A. | |
| dc.date.accessioned | 2021-03-06T10:31:07Z | |
| dc.date.available | 2021-03-06T10:31:07Z | |
| dc.identifier.citation | Bermel R., Comi G., Eralinna J. -. , Leist T. P. , Nicholas R., Oreja-Guevara C., Siva A., Van Wijmeersch B., Wiendl H., Bernasconi C., et al., "Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment", 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Kanada, 14 - 17 Eylül 2016, cilt.22, ss.615-616 | |
| dc.identifier.other | av_eabd0dfa-7243-40ce-9a39-657af4a3920f | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/154190 | |
| dc.language.iso | eng | |
| dc.subject | Tıp | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | Nöroloji | |
| dc.subject | Yaşam Bilimleri | |
| dc.subject | Temel Bilimler | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | NEUROSCIENCES | |
| dc.subject | Sinirbilim ve Davranış | |
| dc.subject | Yaşam Bilimleri (LIFE) | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | KLİNİK NEUROLOJİ | |
| dc.subject | Klinik Tıp | |
| dc.title | Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment | |
| dc.type | Bildiri | |
| dc.contributor.department | Cleveland Clinic Foundation , , | |
| dc.identifier.volume | 22 | |
| dc.contributor.firstauthorID | 149955 |
Bu öğenin dosyaları:
| Dosyalar | Boyut | Biçim | Göster |
|---|---|---|---|
|
Bu öğe ile ilişkili dosya yok. |
|||
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Bildiri [64839]